Table 5.
Ongoing treatment studies evaluating MoAbs in endometrial cancer patients.
| Protocol number | Disease stage | Target therapy | Adjuvant treatment | Study phase | PI |
|---|---|---|---|---|---|
| NCT01010126 | Endometrial cancer | Bevacizumab | Temsirolimus | Phase II | Charles Erlichman, MD |
|
| |||||
| NCT00977574 | Endometrial cancer | Bevacizumab | Temsirolimus Carboplatin ixabepilone Paclitaxel temsirolimus | Phase II | Carol Aghajanian, MD |
|
| |||||
| NCT01005329 | Endometrial cancer | Bevacizumab | Carboplatin Cisplatin | Phase II | Akila Viswanathan, MD |
| Paclitaxel radiotherapy | |||||
|
| |||||
| NCT01367002 | Uterine serous | Trastuzumab | Carboplatin Paclitaxel | Phase II | Alessandro D Santin, M.D. |
|
| |||||
| NCT01256268 | Endometrial Cancer | Ridaforolimus | Paclitaxel Carboplatin | Phase I | Robert Wenham, M.D. |
|
| |||||
| NCR01244438 | Endometrial Cancer with FGFR mutation | FP-1039 | / | Phase II | Sarah Thayer |
|
| |||||
| NCT01065246 | Epithelial Carcinomas | Catumaxomab | Phase II | Jalid Sehouli, MD | |